Assessing State Medical Cannabis Programs Readiness to Accommodate Patients Impacted by New Federal Hemp Laws

This new policy briefing and guidance document by Americans for Safe Access provides state policymakers with the tools to identify patient populations affected by the new federal hemp law, evaluate their medical cannabis programs' capacity to serve them, and implement policy solutions needed to ensure a compassionate transition before November 2026.

New federal hemp definitions create a fixed deadline that could disrupt access to full-spectrum cannabinoid medicines. This briefing explains what changed, who is at risk, and what state leaders can do now to protect patients.

DOWNLOAD BRIEFING

Executive Summary

In November 2025, Congress changed federal hemp law by defining “industrial hemp” and “hemp-derived cannabinoid products” and adopting a “total THC” standard. These changes narrow what products can be sold as hemp—but they also create a patient access problem. Many full-spectrum products relied on as medicine could disappear from lawful commerce when the law takes effect in 2026.

This briefing is a patient-centered roadmap for state leaders. It explains the policy shift, identifies who is at risk, and lays out practical options states can use now to prevent foreseeable harm.

What the Briefing Covers

  • What changed in federal hemp law, and why the 2026 effective date matters
  • Why millions of patients rely on full-spectrum cannabinoid medicines
  • Why Trump's Executive Order and even cannabis rescheduling won't protect access
  • What states can do now: emergency rules, legislative options, and patient-first program reforms
  • How state experiences will support the transition to a national medical cannabis framework

Bottomline: Silence from state leaders today will mean suffering for patients tomorrow.

What States Can Do Now

States are not powerless. This briefing equips policymakers and regulators with practical options—ranging from emergency rulemaking to legislative fixes—that operate within state medical cannabis authority and within new federal limits.

  • Emergency access protections: Targeted state actions to ensure patients can transition into regulated medical cannabis programs
  • Program upgrades: Remove barriers that push patients out of medical programs (cost, access deserts, product availability)
  • Patient-first guardrails: Ensure medical needs aren’t crowded out as adult-use markets expand
  • Product safety alignment: Strengthen testing, labeling, and oversight to protect patients and public health

Protecting Patient Access Resources:

ASA Analysis:

TAKE ACTION TO PROTECT PATIENT ACCESS

Become an ASA member and help protect patient access

Monthly Donor Button